Laurus Labs Limited
Corporate Office
2nd Floor, Serene Chambers, Road No. 7
Banjara Hills, Hyderabad - 500034, Telangana, India
T +91 40 39804333 / 2342 0500 / 501
F +91 40 3980 4320

LAURUS Labs
Knowledge . Innovation . Excellence

November 08, 2019

To	To
The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25th Floor, Dalal Street Mumbai – 400001 **Code: 540222**	The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East) Mumbai – 400 051 **Code: LAURUSLABS**

Dear Sirs,

Sub: Press Release- Laurus Labs completed the USFDA Inspection of its FDF & API Integrated Facility, Unit 2, at Visakhapatnam

The Company is pleased to announce that the USFDA Inspection of its FDF & API Integrated Facility, Unit 2,at Visakhapatnam has been completed with two observations which are procedural in nature.

This is a product pre-approval audit by USFDA, and no data integrity issues were observed in the inspection. The inspection was carried out from 04 November, 2019 – 08 November, 2019.

A press release to this extent is also attached for your information and records.

Thanking you,

Yours sincerely,
For Laurus Labs Limited

LAURUS LABS LIMITED Hyderabad

G. Venkateswar Reddy
Company Secretary

Encl: As above

PRESS RELEASE

LAURUS LABS COMPLETED THE USFDA INSPECTION OF ITS FDF & API INTEGRATED FACILITY, UNIT 2, AT VISAKHAPATNAM.

Hyderabad, November 08, 2019, Laurus Labs Ltd. (Laurus BSE: 540222, NSE: Lauruslabs, ISIN: INE947Q01010)

Laurus Labs Limited, a leading research and development driven pharmaceutical company has completed the US Food and Drug Administration (USFDA) inspection of its Unit – 2 (FDF&API integrated facility), located at APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh, with two observations which are procedural in nature.

This is a product pre-approval audit by USFDA, and no data integrity issues were observed in the inspection. The inspection was carried out from 04 November, 2019 – 08 November, 2019.

About Laurus Labs Limited

Laurus Labs is a leading research driven Pharmaceutical Manufacturing Company in India. We have grown to become one of the leading manufacturers of API for Anti-Retroviral (ARV), Oncology, Cardiovascular, Anti-Diabetics, Anti-Asthma and Gastroenterology. We are thriving on growth opportunities in formulation manufacturing to service all leading markets of North America, Europe and Low Middle Income Countries (LMIC). We are driving growth opportunities in Contract Development and Manufacturing through our Synthesis business. Most of our manufacturing facilities are approved by major regulatory authorities USFDA, WHO-Geneva, UK-MHRA etc. Our approach remains to identify and invest ahead of time with strategic investments in State-of-the-Art R&D and Manufacturing Infrastructure enabling us to become a quality supplier of high volume products. **Corporate Identification No: L24239AP2005PLC047518**

For more information about us, please visit http://www.lauruslabs.com or Contact particulars:

Pavan Kumar N
Laurus Labs Ltd.
Tel: +91 40 3980 4380
Email: mediarelations@lauruslabs.com